This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Science 37 Holdings Toekomstige groei
Future criteriumcontroles 1/6
Science 37 Holdings is forecast to grow earnings and revenue by 66.7% and 17.5% per annum respectively while EPS is expected to grow by 67.9% per annum.
Belangrijke informatie
66.7%
Groei van de winst
67.9%
Groei van de winst per aandeel
| Life Sciences winstgroei | 17.5% |
| Inkomstengroei | 17.5% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 30 Jan 2024 |
Recente toekomstige groei-updates
Recent updates
Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks
Dec 18
Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)
Apr 17Science 37, Syapse team for faster patient enrollment in cancer trials
Aug 18Science 37 reports Q2 mixed earnings; narrows FY22 guidance
Aug 11Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
May 13Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans
Apr 11Science 37: Pioneering Decentralized Clinical Trials
Jan 02We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth
Nov 04Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 95 | 3 | -18 | 30 | 3 |
| 12/31/2025 | 75 | -25 | -28 | 3 | 3 |
| 12/31/2024 | 63 | -38 | -44 | -9 | 4 |
| 12/31/2023 | 58 | -73 | -81 | -46 | 4 |
| 9/30/2023 | 60 | -125 | -74 | -48 | N/A |
| 6/30/2023 | 62 | -134 | -84 | -58 | N/A |
| 3/31/2023 | 66 | -121 | -98 | -67 | N/A |
| 12/31/2022 | 70 | -51 | -107 | -75 | N/A |
| 9/30/2022 | 75 | -50 | -115 | -82 | N/A |
| 6/30/2022 | 73 | -41 | -108 | -78 | N/A |
| 3/31/2022 | 66 | -43 | -83 | -57 | N/A |
| 12/31/2021 | 60 | -94 | -57 | -36 | N/A |
| 9/30/2021 | 50 | -42 | -37 | -23 | N/A |
| 6/30/2021 | 43 | -35 | -33 | -23 | N/A |
| 3/31/2021 | 33 | -33 | -33 | -26 | N/A |
| 12/31/2020 | 24 | -32 | -32 | -25 | N/A |
| 12/31/2019 | 14 | -18 | -20 | -16 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: SNCE is forecast to remain unprofitable over the next 3 years.
Winst versus markt: SNCE is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: SNCE is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: SNCE's revenue (17.5% per year) is forecast to grow faster than the US market (8.1% per year).
Hoge groei-inkomsten: SNCE's revenue (17.5% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if SNCE's Return on Equity is forecast to be high in 3 years time